Tempus AI (NASDAQ:TEM) Shares Down 1.9% – Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM) was down 1.9% during trading on Tuesday . The stock traded as low as $33.00 and last traded at $33.22. Approximately 417,510 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 1,623,468 shares. The stock had previously closed at $33.87.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Loop Capital raised their price target on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Bank of America boosted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Piper Sandler reissued a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Wolfe Research initiated coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Trading Down 0.3 %

The firm’s 50-day moving average is $49.28 and its 200 day moving average is $46.70. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Activity

In other Tempus AI news, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the transaction, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 845,041 shares of company stock valued at $35,125,473 over the last ninety days.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. NEA Management Company LLC bought a new stake in shares of Tempus AI in the second quarter valued at $160,048,000. Novo Holdings A S purchased a new position in shares of Tempus AI during the 2nd quarter valued at about $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in Tempus AI during the second quarter valued at about $128,133,000. ARK Investment Management LLC grew its position in Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after acquiring an additional 1,855,459 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.